Anti-TNF alpha antibody [cA2 (Infliximab)] - Human IgG1 (Chimeric)
- Recombinant
- Lab Essentials
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Human Recombinant Monoclonal TNF alpha antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human TNF.
View Alternative Names
TNFA, TNFSF2, TNF, Tumor necrosis factor, Cachectin, TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a
- WB
Unknown
Western blot - Anti-TNF alpha antibody [cA2 (Infliximab)] - Human IgG1 (Chimeric) (AB275974)
The expected band size (26.9 kDa) is seen in the human-derived samples, as well as a band corresponding to dimers.
10% SDS PAGE gel.
All lanes:
Western blot - Anti-TNF alpha antibody [cA2 (Infliximab)] - Human IgG1 (Chimeric) (ab275974) at 1.5 µg/mL
Lane 1:
Mouse liver tissue lysate
Lane 2:
Mouse spinal cord tissue lysate
Lane 3:
Mouse testis tissue lysate
Lane 4:
Mouse colon tissue lysate
Lane 5:
Human thyroid tumour tissue lysate
Predicted band size: 25 kDa
false
Reactivity data
Product details
Recombinant monoclonal antibody to TNF alpha. Variable regions (i.e. specificity) from the therapeutic antibody cA2 (Infliximab).
This is a human chimeric antibody created for improved compatibility with existing reagents, assays and techniques.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Heliyon 9:e17366 PubMed37426804
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com